Opthea (OPT) Competitors $3.89 +0.15 (+4.01%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OPT vs. COGT, PAHC, RLAY, CDMO, SANA, TYRA, SEPN, AVDL, IMTX, and CRONShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Septerna (SEPN), Avadel Pharmaceuticals (AVDL), Immatics (IMTX), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Cogent Biosciences Phibro Animal Health Relay Therapeutics Avid Bioservices Sana Biotechnology Tyra Biosciences Septerna Avadel Pharmaceuticals Immatics Cronos Group Cogent Biosciences (NASDAQ:COGT) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings. Which has stronger earnings & valuation, COGT or OPT? Cogent Biosciences has higher earnings, but lower revenue than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$2.48-3.24Opthea$120K4,422.61-$220.24MN/AN/A Does the media prefer COGT or OPT? In the previous week, Cogent Biosciences had 11 more articles in the media than Opthea. MarketBeat recorded 15 mentions for Cogent Biosciences and 4 mentions for Opthea. Opthea's average media sentiment score of 0.91 beat Cogent Biosciences' score of 0.19 indicating that Opthea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Opthea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend COGT or OPT? Cogent Biosciences currently has a consensus price target of $14.33, suggesting a potential upside of 78.50%. Opthea has a consensus price target of $12.00, suggesting a potential upside of 208.48%. Given Opthea's stronger consensus rating and higher probable upside, analysts clearly believe Opthea is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Opthea 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community favor COGT or OPT? Cogent Biosciences received 271 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 70.59% of users gave Cogent Biosciences an outperform vote while only 53.13% of users gave Opthea an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes28870.59% Underperform Votes12029.41% OptheaOutperform Votes1753.13% Underperform Votes1546.88% Is COGT or OPT more profitable? Opthea's return on equity of 0.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Opthea N/A N/A N/A Which has more risk & volatility, COGT or OPT? Cogent Biosciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Do institutionals and insiders hold more shares of COGT or OPT? 56.0% of Opthea shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryOpthea beats Cogent Biosciences on 8 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$480.24M$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E RatioN/A44.8387.9117.30Price / Sales4,422.61265.291,258.3378.69Price / CashN/A192.9043.8235.97Price / Book-2.993.965.324.79Net Income-$220.24M-$41.02M$122.78M$225.07M7 Day Performance10.51%-1.80%-0.19%1.52%1 Month Performance23.10%0.47%3.73%4.69%1 Year Performance40.94%-1.73%27.32%20.91% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea3.4498 of 5 stars$3.89+4.0%$12.00+208.5%+49.6%$480.24M$120,000.000.008Gap UpCOGTCogent Biosciences1.5115 of 5 stars$7.57-3.4%$14.83+95.9%+64.5%$836.20MN/A-3.0580Analyst ForecastShort Interest ↑News CoveragePAHCPhibro Animal Health4.2464 of 5 stars$20.27+1.1%$20.50+1.1%+83.8%$821.00M$1.05B47.141,860Analyst RevisionRLAYRelay Therapeutics2.4346 of 5 stars$4.78+7.4%$20.50+328.9%-57.2%$800.09M$10.01M-1.83330Analyst ForecastShort Interest ↑News CoverageCDMOAvid Bioservices2.3589 of 5 stars$12.43+0.2%$12.25-1.4%+97.9%$795.06M$150.45M-5.20320SANASana Biotechnology3.0376 of 5 stars$3.46-5.5%$14.25+311.8%-48.4%$772.51MN/A-2.47380Gap DownTYRATyra Biosciences2.6007 of 5 stars$15.10-0.7%$30.50+102.0%+28.9%$764.11MN/A-9.3820SEPNSepterna1.795 of 5 stars$17.00-5.5%$43.67+156.9%N/A$754.85M$981,000.000.00N/ANegative NewsAVDLAvadel Pharmaceuticals3.634 of 5 stars$7.82-1.0%$21.00+168.5%-49.6%$753.55M$138.16M-9.9070Positive NewsIMTXImmatics1.6053 of 5 stars$6.25-2.8%$16.67+166.7%-52.2%$745.98M$115.50M-9.47260Short Interest ↑News CoverageGap UpCRONCronos Group2.4952 of 5 stars$1.95-1.5%$3.00+53.8%-1.0%$745.48M$111.23M-15.00450Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies COGT Alternatives PAHC Alternatives RLAY Alternatives CDMO Alternatives SANA Alternatives TYRA Alternatives SEPN Alternatives AVDL Alternatives IMTX Alternatives CRON Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts